top of page

Vera Study

Study for patients with IgA nephropathy

Origin 3.png


IgA Nephropathy (IgAN, also known as Berger’s disease) is a rare autoimmune disease that can slowly damage the kidneys and may eventually lead to kidney failure. Managing IgAN is challenging—sometimes overwhelming.

Vera Therapeutics is conducting a clinical study in IgAN. The ORIGIN 3 study is exploring how atacicept, the study medication, might help prevent kidney damage in people with IgAN by targeting the upstream source of disease.


  • Are 18 years or older

  • Diagnosed with IgAN, confirmed by a kidney biopsy within the past 10 years

  • On a stable, prescribed regimen of an ACE inhibitor or ARB medication for blood pressure for at least 3 months

**There are other criteria that potential participants must meet in order to qualify for the study**

Origin 3.png

If you’re interested in participating in one of our Research Studies:



ext 2150, 2170 or 2190

bottom of page